fashion -WSS

fashion

author：Wikipedia 2025-09-28 01:36:00 - browse：37

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Inaction leaves children at risk from dangerous chemotherapy drug

WSS

Bernie brings in new pharma CEOs to talk drug prices

Dog Aging Project founders on what lies ahead after losing funding

Why Novartis is going to walk from its acquisition of MorphoSys

Gene therapy for Afghan refugees’ infant will be fully covered

Dog Aging Project founders on what lies ahead after losing funding

Why CTE doesn’t keep Americans from enjoying the Super Bowl

focus

fashion

explore

Psychedelics group wrestles with new pharma identity

The inclusion problem at the heart of rehabilitation research

Novavax promises a turnaround & Lilly roils the obesity market

Bernie brings in new pharma CEOs to talk drug prices

State Dept. review finds Biden bears some blame for Afghanistan failures

Devoted Health’s losses in Medicare Advantage persist

Drug repurposing or repositioning? The language matters

Cardiologists urge adding sexual orientation, gender identity to health records

Hollywood unions extend contract negotiations for actors

The Biogen Aduhelm mess could happen again

hotspot

What causes osteoarthritis? Researchers study link to brain protein

Readout LOUD: Venture capital, Gilead, and more M&A

What’s missing from the debate over nursing home staff minimums

AI gets buy

Readout LOUD: Venture capital, Gilead, and more M&A

Updated Covid vaccine has 54% effectiveness, new study suggests

leisure time

focus

leisure time

hotspot